Sinovac Biotech Ltd.

Equities

SVA

AGP8696W1045

Pharmaceuticals

Delayed Nasdaq 04:00:00 2019-02-22 pm EST 5-day change 1st Jan Change
6.47 USD -0.31% Intraday chart for Sinovac Biotech Ltd. -.--% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd. CI
Scientists see risk of lost opportunity for long COVID research in China RE
Sinovac Biotech Ltd. Reports on the Clinical Trial Progress of Its Anti-Covid-19 Antibody Sa55 Injection CI
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital made an offer to acquire 10.04% stake in Sinovac Biotech Ltd. for an offer per share of $0.03. CI
Sinovac Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sinovac Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
China mRNA vaccine development jumps into high gear RE
Sinovac Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
BioNTech COVID-19 Vaccines Shipped to China From Germany MT
Sinovac Biotech Says World Health Organization Approved Varicella Vaccine MT
Sinovac Varicella Vaccine Prequalified by WHO CI
Indonesia approves first home-grown COVID vaccine for emergency use - media RE
Sinovac Biotech Gets Chilean Health Regulator Approval to Start Clinical Trial for Its Omicron Containing COVID-19 Vaccine MT
Sinovac Biotech Ltd. Announces the Chilean Public Health Institute Approve Phase II Clinical Trial for Its Inactivated Omicron Strain CI
SINOVAC COVID-19 Vaccine Approves for Use in Children Above 6 months of Age in Hong Kong CI
Sinovac Biotech Initiates Phase 3 Clinical Trial for Quadrivalent Influenza Vaccine in Chile MT
Sinovac Biotech Ltd. Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile CI
Sinovac Biotech Says Brazilian Health Regulator Approves COVID-19 Vaccine for Use in Children Ages 3 to 5 MT
Sinovac Biotech Ltd. Announces its COVID-19 Vaccine Authorized by Brazilian Health Regulatory Agency for Emergency Use in Kids Aged 3-5 in Brazil CI
Sinovac Biotech Ltd. Joins Hands with University of Hong Kong Clinical Trials Centre Research Team and Gleneagles Hospital Hong Kong to Kick Off A Clinical Trial of an Omicron-Specific Inactivated Vaccine for Booster Use in Hong Kong, China CI
Sinovac Biotech Secures Conditional Registration in South Africa for COVID-19 Vaccine MT
Sinovac's COVID-19 vaccine conditionally registered in South Africa RE
Sinovac Biotech Ltd. Announces South African Health Products Regulatory Authority Granted Conditional Registration to SINOVAC CoronaVac CI
Sinovac Biotech Ltd. Polio Vaccine Prequalified by WHO CI
Sinovac Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chart Sinovac Biotech Ltd.
More charts
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
More about the company
  1. Stock Market
  2. Equities
  3. SVA Stock
  4. News Sinovac Biotech Ltd.
  5. Market Chatter: Sinovac Biotech's COVID-19 Vaccine 67% Effective in Chilean Study